In this article from Seeking Alpha, the author discusses four dividend aristocrats, providing ratings on which to buy and sell. Dividend aristocrats are companies that have consistently increased their dividends for at least 25 consecutive years. These companies are often seen as stable and reliable investment opportunities.
The first company mentioned in the article is Johnson & Johnson (JNJ). The author rates JNJ as a buy due to its long history of dividend increases and strong financials. The company has a diverse portfolio of products, which helps to mitigate risk and provides stability. Additionally, the author notes that JNJ has a strong balance sheet and a solid dividend yield.
The second company discussed is Chevron (CVX). The author rates CVX as a sell due to concerns about the company’s future dividend sustainability. With oil and gas prices experiencing volatility and the transition to cleaner energy sources, the author suggests that CVX may struggle to maintain its dividend growth. Furthermore, the author highlights the company’s high debt levels as a potential risk.
Next, the article moves on to AbbVie (ABBV). The author rates ABBV as a buy, citing the company’s strong dividend growth and attractive valuation. ABBV is a pharmaceutical company that focuses on research and development in areas such as immunology and oncology. The author believes that ABBV’s diverse pipeline of drugs will help drive future growth and dividend increases.
Lastly, the author discusses 3M (MMM). The author rates MMM as a sell due to concerns about the company’s declining revenue and potential future litigation costs. MMM is a diversified technology company that operates in various sectors, including healthcare, transportation, and consumer goods. The author points out that MMM’s revenue has been declining in recent years, and the company has faced legal challenges related to products such as firefighting foam.
Overall, the author provides a mix of buy and sell ratings for these dividend aristocrats. It is important for investors to conduct their own research and consider their investment goals and risk tolerance before making any investment decisions.
H2: Johnson & Johnson (JNJ)
– Rated as a buy
– Long history of dividend increases
– Diverse product portfolio
H2: Chevron (CVX)
– Rated as a sell
– Concerns about future dividend sustainability
– Volatility in oil and gas prices
H2: AbbVie (ABBV)
– Rated as a buy
– Strong dividend growth
– Attractive valuation
– Diverse pipeline of drugs
H2: 3M (MMM)
– Rated as a sell
– Declining revenue
– Potential litigation costs
– Diversified technology company
Overall, it is important for investors to conduct their own research and consider their investment goals and risk tolerance before making any investment decisions.